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BACKGROUND Long lesions account for a signiﬁcant proportion of
percutaneous coronary intervention and it has been identiﬁed as one
of the predictors which inﬂuence risk of angiographic and clinical
restenosis. However, newer generation drug-eluting stents particu-
larly of long length avoid incomplete coverage of the diseased
segment of the long lesion and thereby minimize the occurrence of
restenosis. Therefore, in this LONG-FLEX registry, we aimed to assess
clinical outcomes of real-world patients who were successfully treated
with long length Supraﬂex (Sahajanand Medical Technologies Pvt.
Ltd., Surat, India), a novel biodegradable polymer coated sirolimus-
eluting stent.
METHODS This retrospective, non-randomized and observational
registry included 240 consecutive patients who were treated with long
Supraﬂex stent (length 40mm) in view of long coronary lesions from
nine different clinical sites of India. The primary endpoint of the study
was 9-month incidence ofmajor adverse cardiac events (MACE) deﬁned
as a composite of cardiac death, myocardial infarction (MI), target
lesion revascularization (TLR) and target vessel revascularization
(TVR). We also assessed stent thrombosis (ST) according to the Aca-
demic Research Consortium deﬁnition at 9-month clinical follow-up.
RESULTS The study population consisted of 240 consecutive pa-
tients who were successfully treated with long study stents between
July, 2012 and May, 2014. The study population predominantly
included high risk patients with 120 (50.0%) hypertensive patients
and 56 (23.3%) diabetic patients which reﬂected real-world scenario.
A total of 248 lesions were intervened with a total of 287 study
stents. The average number of implanted stents per lesion was
1.20.4. Clinical follow-up at 9-month was completed in 236
(98.33%) patients. At 9-month clinical follow-up, 1 (0.42%) died due
to cardiac event, 4 (1.69%) had MI and 2 (0.85%) underwent TLR.
Thus, nine-month clinical follow-up demonstrated low rate of MACE
(n¼7; 2.97%). A total of 4 (1.69%) incidences of ST, 1 (0.42%) deﬁnite
ST and 3 (1.27%) probable ST, were observed at 9-month clinical
follow-up.
CONCLUSIONS The nine-month clinical outcomes of this “real-
world” registry demonstrated safety and efﬁcacy of Supraﬂex stent in
patients receiving long study stents (stent length 40 mm) implanted
over long length coronary lesions.
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BACKGROUND Only limited long-term safety and efﬁcacy data from
large randomized clinical trials are available on second-generation
drug-eluting stents (DES). In a head-to-head comparison, we assessed
the 5-year safety and efﬁcacy of the zotarolimus eluting Resolutestent (Medtronic) versus the everolimus-eluting Xience V stent
(Abbott Vascular).
METHODS The TWENTE trial is an investigator-initiated, patient-
blinded, randomized, non-inferiority study with limited exclusion
criteria (all coronary syndromes except for STEMI), performed in a
broad patient population that reﬂects routine clinical practice. Pa-
tients (n¼1,391; 81.4% of the entire eligible patient population) were
randomly assigned to percutaneous coronary intervention (PCI) with
Resolute (n¼697) or Xience V stents (n¼694). Similarity in one-year
clinical outcome between trial participants and the non-enrolled pa-
tient population has previously been reported in detail. The primary
endpoint is target vessel failure (TVF), a composite of cardiac death,
target vessel-related myocardial infarction (MI), and target vessel
revascularization (TVR). Secondary endpoints included the individual
components of the primary endpoint and the incidence of stent
thrombosis. An independent external research organization per-
formed the clinical event adjudication.
RESULTS In the study population (64.210.8 years; 72.5% male)
non-ST-elevation acute coronary syndromes were present in 52.6%
of the patients and 21.6% of patients were diabetics. A large pro-
portion of patients was treated for complex type B2 or C lesions
(70.1%) and “off-label” indications for DES use (77.4%). The 5-year
incidence of the primary endpoint TVF and various secondary
endpoints will be presented for both DES groups. These include the
components of TVF, stent thrombosis, and various composite clin-
ical endpoints such as target lesion failure (TLF), major adverse
cardiac events (MACE), and patient-oriented composite endpoint
(POCE).
CONCLUSIONS We will report the ﬁnal 5-year outcome of patients
enrolled in the randomized TWENTE trial, which compared the
Resolute zotarolimus-eluting stent versus the Xience V everolimus-
eluting stent.
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BACKGROUND Patients with diabetes mellitus (DM) treated with
ﬁrst generation drug-eluting stents (DES) remain at higher risk of
major adverse cardiac events (MACE) and stent thrombosis (ST)
compared with non-diabetics. Long-term data on newer generation
DES in diabetics are sparse. We assess and compare the incidence of
MACE and ST at 3 y after implantation of Biolimus A9-eluting
coronary stents (BioMatrix, BioMatrix Flex) in diabetic and non-
diabetic patients.
METHODS A total of 1315 diabetic patients (408 insulin dependent
[IDDM], 907 non-insulin dependent[NIDDM]) and 4154 non-diabetic
patients received a BioMatrix or BioMatrix Flex coronary stent,
and were enrolled in e-BioMatrix, a prospective international multi-
center registry. The primary outcome measure of the present analysis
was the 3-y incidence of MACE (composite of cardiac death, myocar-
dial infarction [MI] or clinically driven target vessel revascularization
[TVR]). ARC deﬁnite or probable ST were secondary outcome
measures.
RESULTS Patients with DM were older than non-diabetics (mean age
64.610.2 vs. 62.811.1 y; p<0.001) and had a higher Charlson co-
morbidity index (2.11.6 vs 0.61.0; p<0.001). A high percentage of
49.8% presented with acute coronary syndromes. Diabetic patients
had more lesions (1.470.80 vs 1.420.76; p¼0.04), more vessels
treated (1.230.49 vs. 1.190.45; p¼0.006), and smaller stent di-
ameters (2.950.36 vs 3.00.36; p<0.001), while the total stent length
was similar. At 3y follow up (compliance 89.6%) 12.2% of DM patients
and 8.0% of non-DM patients had a MACE event (p<0.001). Patients
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similar for patients with NIDDM and non-diabetics. Clinically driven
TVR was 5.97% for diabetics and 3.38% for non-diabetic patients.
Deﬁnite or probable ST occurred in 0.9% for diabetic and non-diabetic
patients, and in 1.0% of patients with IDDM.
CONCLUSIONS In this registry, diabetic patients receiving a Biolimus
A9–eluting DES had a signiﬁcantly higher rate of MACE than non-
diabetics, but similar and low rates of ARC deﬁnite or probable stent
thrombosis at 3 y of follow up.
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BACKGROUND The e-Biomatrix registry is a prospective, multi-
center, observational registry investigating the long-term clinical
events after treating a “real world, all-comers” patient population
with either BioMatrix or BioMatrix Flex stents. This BA9-
eluting stent (BES) has an abluminal biodegradable polymer coating,
which disappears within 9 months, and is intended to prevent the
late events that may be associated with the existence of durable
polymer. This work presents the inﬂuence of comorbidities on out-
comes in this setting. We present the ﬁnal result of our study on the
impact of comorbidities (using the Charlson’s comorbidity index) on
clinical outcomes.
METHODS We used the Charlson comorbidity index (CCI), a scoring
system involving weighting factors on the basis of disease severity,
including cardiovascular diseases, diabetes, renal failure, chronic
infections and malignant tumors. Among 5472 patients in this reg-
istry, 2953 (54%) had at least one comorbidity, of which the most
common comorbidities were prior myocardial infarction (24.9% of
the population), diabetes mellitus (24.1%), peripheral vascular dis-
ease (6.8%), congestive heart failure (5.2%), chronic obstructive
pulmonary disease (5.2%), cerebral vascular disease (5.7%) and renal
failure (2.7%). Four patient subgroups with Charlson comorbidity
indices equal to 0, 1, 2, and 3 are deﬁned as follows: CCI-0 (no
comorbidity; n¼ 2517), CCI-1 (CCI¼1; n¼1709), CCI-2 (CCI¼2; n¼694),
CCI3 (n¼550). With increasing CCI, patients were older, had higher
rates of hypertension, hypercholesterolemia, and obesity, but were
less often current smokers. They had undergone increasingly often a
prior PCI or CABG and had more often decreased LV ejection frac-
tion. LVEF <40%: CCI-0: 4.78%, CCI-1: 6.5%, CCI-2: 14.19%, CCI3:
28.1%; p<0.01. Compared to the other groups, patients with CCI3
underwent PCI less often for STEMI (CCI-0: 41.7%, CCI-1: 30.3%,
CCI-2: 25.7%, CCI3: 13.8%).
RESULTS At 1 year, the comparison of the subgroups by the Kaplan-
Meier curves suggested a direct correlation between CCI and MACE,
but not between CCI and bleeding or stent thrombosis. However, in a
multivariate analysis CCI was shown to be no longer an independent
predictor of MACE. The ﬁnal 36-months data including the primary
endpoint (MACE), Mortality, MI, stent thrombosis and bleeding, is in
the process of being analyzed and will be reported at the time of
presentation. Furthermore, the results of the multivariate analysis
will be reported to identify the independent predictors of 36-month
mortality, MACE, and major bleeding.
CONCLUSIONS This large international study demonstrates the
impact of comorbidities on long-term safety and efﬁcacy outcomes in
patients undergoing PCI. The complete ﬁnal 3-year follow-up analysis
will be available at the time of the meeting.
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BACKGROUND A post marketing clinical follow-up study was
conducted evaluating the continued safety and effectiveness of the
CE-mark approved DESyne Novolimus Eluting Coronary Stent
System (NECSS) (Elixir Medical, Sunnyvale, CA), a Co-Cr stent with
a durable biocompatible polymer and Novolimus, a macrocyclic
lactone mTOR inhibitor. The drug dose is 5 mg per mm of stent
length.
METHODS A total of 57 patients were enrolled into the EXCELLA Post-
marketing Clinical Follow-up (PMCF) study. All were treated with the
DESyne NECSS for de novo lesions in native coronary arteries with a
reference vessel diameter between 2.5 and 4.0mm treatable with
stents between 14 and 38 mm in length. Patient data were analyzed
for the clinical endpoints of major adverse cardiac events (MACE)
deﬁned as: cardiac death, target vessel MI, clinically-indicated target
lesion revascularization (TLR); target vessel revascularization and
stent thrombosis at 1, 9, 12 and 24 months. The study was approved
the local Ethics Committees and all patients provided informed
consent.
RESULTS Patients were enrolled between February 2014 and May
2014, in Germany, Jordan and Spain. After the index procedure, pa-
tients were contacted at 1, 9 and 12 months either via an ofﬁce visit or
telephonically. The mean age of patients was 62 years; 38.6% were
diabetics and 72% presented with hypercholesterolemia and 72% with
hypertension and 12.3% had unstable angina. Baseline lesion charac-
teristics revealed 51% type C lesion with a mean reference vessel
diameter of 2.84  0.45mm and lesion length of 17.27  8.73mm.
Clinically, the DESyne NECSS demonstrates excellent safety with no
clinical events reported through 30 days and continued low MACE
rates through 12 months; with the full demographic, lesion and clin-
ical data through 12 months to be presented.
CONCLUSIONS The DESyne NECSS continues to demonstrate excel-
lent clinical safety similar to the clinical safety results seen in the
pivotal EXCELLA II Randomized Study. Demographic and clinical re-
sults through 12 months will be presented.
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BACKGROUND The Resolute IntegrityTM zotarolimus-eluting stent
(ZES; Medtronic, Inc.) is designed with a single continuous wire
formed into a repeating sinusoidal pattern (as compared with discrete
rings with the previous Resolute ZES) with the goal to enhance
deliverability. The objective of RESOLUTE INTEGRITY US Zotar-
olimus-Eluting Coronary Stent System Clinical Study is to investigate
outcomes with Resolute Integrity ZES.
METHODS The RESOLUTE INTEGRITY US study is a multi-center,
single-arm, open label study in the United States that enrolled pa-
tients with de novo lesions with length 30 mm and vessel diameter
of 2.25 to 4.2 mm. Clinical outcomes have not been previously re-
ported. Patients will have been followed for two years by the time of
TCT 2015.
RESULTS The RESOLUTE INTEGRITY US study enrolled 230 patients
(251 lesions); 42% had diabetes mellitus, including 17% with insulin-
dependent diabetes mellitus, 24% prior myocardial infarction, 83% of
